Renal cell carcinoma (RCC) is a common kind of renal or kidney
cancer. Transitional cell carcinoma (TCC) is also a key type of
kidney cancer, but is less prevalent amongst individuals as compared
to RCC. Surgical procedures alone are sometimes not sufficient for
the treatment of these cancers, particularly in cases where patients
develop metastatic cancers. This is when additional treatment
regimens are recommended and immunotherapies and targeted therapies
come into play. Kidney cancer drugs are considered to increase the
overall lifespan, particularly in patients having an advanced stage
of metastatic tumors.
As mentioned in the report, the increasing occurrence of kidney
cancer and the rising aging population globally are amongst the key
factors stimulating the growth of the market for kidney cancer drugs.
In addition, several novel molecules receiving approval globally is
also a prime factor fuelling the market. On the other hand, the
soaring prices of branded cancer drugs may restrain the growth of the
market. In addition, the rising inclination of the consumers towards
generic drug variants may also have a negative impact on the market’s
development.
In terms of drug, the market is segmented into Sutent (Sunitinib),
Afinitor (Everolimus), Nexavar (Sorafenib), Votrient (Pazopanib),
Avastin (Bevacizumab), Inlyta (Axitinib), Proleukin (Aldesleukin),
and Torisel (Temsirolimus). Amongst these, on the basis of revenue,
Sutent led the market in 2013 owing to Sutent being the majorly
prescribed drug in the first-line treatment for kidney cancer. In
addition, Sutent is also amongst the top studied drugs within its
class for multiple indications, as it targets multiple receptor
tyrosine kinases (RTKs). On the other hand, Votrient is predicted to
emerge as a market leader by 2017 and is expected to surpass Sutent
and all other competitors owing to its unique first-line penetration
and low pricing. Votrient exhibited a whopping CAGR of more than 40%
between 2012 and 2016.
Know About the Demand for Kidney Cancer Drugs at: http://bit.ly/2cCOSJm
Geographically, the report segments the market into Europe, North
America, Asia Pacific, and Rest of the World (RoW). Amongst these,
North America leads the kidney cancer drugs market owing to the
presence of a huge patient pool having different kinds of cancers of
the kidney and the commercial penetration of top branded drugs for
the treatment of kidney cancer in this region.
On the other hand, Asia Pacific is also predicted to grow
exponentially in the market owing to the increasing aging population
and the increasing occurrence of renal cell carcinoma in this region.
Furthermore, the economic advancement of nations such as China,
India, Malaysia, and Singapore will also stimulate the growth of the
market in the region of Asia Pacific.
According to the report, the chief players operating in the market
for kidney cancer drugs are Novartis AG., F. Hoffman-La Roche.,
Pfizer, Inc., Bayer Pharma AG., and GlaxoSmithKline, plc., among
others.
No comments:
Post a Comment